GlassScriptPhysician profile
John A Middleton
NPI 1427160720
$16,802.06
in general payments reported to CMS, 2019-2025
17 companies · $3,417 in 2025
The $3,417 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $1,509 · 2021: $1,947 · 2022: $1,490 · 2023: $1,701 · 2024: $5,135 · 2025: $3,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $6,025 · Food and Beverage: $4,116 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $6,025.00 |
| Food and Beverage | $4,115.99 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $6,053.79 | 2020-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $3,099.33 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,814.67 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $995.63 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $951.48 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $654.76 | 2019-2024 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $642.00 | 2019-2024 | Uzedy |
| Lundbeck LLC | $640.82 | 2019-2024 | Rexulti |
| Indivior INC. | $571.29 | 2020-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $291.26 | 2019-2022 | |
| Allergan, INC. | $268.27 | 2019-2020 | |
| Abbvie INC. | $201.85 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $150.30 | 2022-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $125.70 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $120.30 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.49 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $104.12 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.